ACP 196 Alone or in Combination With Rituximab in Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 06 Nov 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Apr 2022.
- 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2015 Planned number of patients changed from 32 to 36 as reported by ClinicalTrials.gov.